Amphastar Pharmaceuticals (NASDAQ:AMPH) Cut to C at TheStreet

Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by analysts at TheStreet from a “b-” rating to a “c” rating in a research report issued on Thursday, TheStreetRatingsTable reports.

Several other equities analysts have also weighed in on AMPH. ValuEngine lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, September 20th. Zacks Investment Research lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, BidaskClub lowered shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 29th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $24.44.

Shares of Amphastar Pharmaceuticals stock traded down $0.71 on Thursday, hitting $18.41. The company had a trading volume of 600,700 shares, compared to its average volume of 195,968. The firm has a market capitalization of $918.08 million, a P/E ratio of 87.67 and a beta of 1.17. The stock has a 50-day moving average of $19.87 and a 200-day moving average of $20.65. Amphastar Pharmaceuticals has a twelve month low of $16.92 and a twelve month high of $25.43. The company has a debt-to-equity ratio of 0.13, a current ratio of 2.81 and a quick ratio of 1.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.08 by $0.02. The company had revenue of $80.14 million for the quarter, compared to analyst estimates of $78.53 million. Amphastar Pharmaceuticals had a net margin of 16.33% and a return on equity of 5.52%. The company’s revenue was up 6.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.12 earnings per share. Equities analysts predict that Amphastar Pharmaceuticals will post 0.17 EPS for the current year.

In related news, General Counsel Jason B. Shandell sold 7,340 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $21.32, for a total transaction of $156,488.80. Following the transaction, the general counsel now directly owns 147,103 shares of the company’s stock, valued at $3,136,235.96. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Richard K. Prins sold 7,500 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $22.59, for a total transaction of $169,425.00. Following the transaction, the director now directly owns 43,191 shares in the company, valued at $975,684.69. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 354,479 shares of company stock worth $7,415,153. 30.80% of the stock is owned by insiders.

Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC bought a new position in Amphastar Pharmaceuticals during the second quarter worth about $88,000. Bank of Montreal Can grew its stake in Amphastar Pharmaceuticals by 130.7% during the second quarter. Bank of Montreal Can now owns 4,923 shares of the company’s stock worth $104,000 after buying an additional 2,789 shares in the last quarter. Atria Investments LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $449,000. Magnus Financial Group LLC acquired a new stake in Amphastar Pharmaceuticals during the second quarter worth about $204,000. Finally, JPMorgan Chase & Co. grew its stake in Amphastar Pharmaceuticals by 15.4% during the second quarter. JPMorgan Chase & Co. now owns 9,856 shares of the company’s stock worth $205,000 after buying an additional 1,314 shares in the last quarter. 47.21% of the stock is currently owned by institutional investors and hedge funds.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Read More: What is Put Option Volume?

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.